Retinal and optic nerve diseases.

A variety of disease processes can affect the retina and/or the optic nerve, including vascular or ischemic disease, inflammatory or infectious disease, and degenerative disease. These disease processes may selectively damage certain parts of the retina or optic nerve, and the specific areas that are damaged may have implications for the design of potential therapeutic visual prosthetic devices. Outer retinal diseases include age-related macular degeneration, pathologic myopia, and retinitis pigmentosa. Although the retinal photoreceptors may be lost, the inner retina is relatively well-preserved in these diseases and may be a target for retinal prosthetic devices. Inner retinal diseases include retinal vascular diseases such as diabetic retinopathy, retinal venous occlusive disease, and retinopathy of prematurity. Other retinal diseases such as ocular infections (retinitis, endophthalmitis) may affect all retinal layers. Because the inner retinal cells, including the retinal ganglion cells, may be destroyed in these diseases (inner retinal or whole retinal), prosthetic devices that stimulate the inner retina may not be effective. Common optic nerve diseases include glaucoma, optic neuritis, and ischemic optic neuropathy. Because the ganglion cell nerve fibers themselves are damaged, visual prosthetics for these diseases will need to target more distal portions of the visual pathway, such as the visual cortex. Clearly, a sound understanding of retinal and optic nerve disease pathophysiology is critical for designing and choosing the optimal visual prosthetic device.

[1]  M. Davis,et al.  Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant , 1997 .

[2]  E. de Juan,et al.  A conjunctival retractor for retinal surgery. , 1987, Archives of ophthalmology.

[3]  S. Bursell,et al.  Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. , 1997, American journal of ophthalmology.

[4]  C. Kufta,et al.  Feasibility of a visual prosthesis for the blind based on intracortical microstimulation of the visual cortex. , 1996, Brain : a journal of neurology.

[5]  G. Fishman,et al.  A genetic analysis of retinitis pigmentosa. , 1983, The British journal of ophthalmology.

[6]  R. Beck,et al.  The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. , 1993, The New England journal of medicine.

[7]  C. Curcio,et al.  Photoreceptor loss in age-related macular degeneration. , 1996, Investigative ophthalmology & visual science.

[8]  W. Green,et al.  The histology of human glaucoma cupping and optic nerve damage: clinicopathologic correlation in 21 eyes. , 1979, Ophthalmology.

[9]  D. Hodge,et al.  Incidence of Nonarteritic Anteripr Ischemic Optic Neuropathy , 1997 .

[10]  S. Hayreh,et al.  Anterior ischemic optic neuropathy. VII. Incidence of bilaterality and various influencing factors. , 1987, Ophthalmology.

[11]  S. Wisniewski,et al.  Retinal detachment in the endophthalmitis vitrectomy study. , 2000, Archives of ophthalmology.

[12]  A. Patz Retinal neovascularisation: early contributions of Professor Michaelson and recent observations. , 1984, The British journal of ophthalmology.

[13]  S. Charles,et al.  Surgical decompression of branch retinal vein occlusions. , 1988, Archives of ophthalmology.

[14]  A. Sommer,et al.  Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. , 1991, Archives of ophthalmology.

[15]  Verteporfin Roundtable Participants GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES , 2002, Retina.

[16]  M. Kupersmith,et al.  Aspirin Reduces the Incidence of Second Eye NAION: A Retrospective Study , 1997, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[17]  S S Hayreh,et al.  Classification of central retinal vein occlusion. , 1983, Ophthalmology.

[18]  H. Flynn,et al.  Nosocomial endophthalmitis survey. Current incidence of infection after intraocular surgery. , 1991, Ophthalmology.

[19]  S. Fine,et al.  Pathologic myopia and choroidal neovascularization. , 1981, American journal of ophthalmology.

[20]  F. H. Theodore Etiology and diagnosis of fungal postoperative endophthalmitis. , 1978, Ophthalmology.

[21]  I. Constable,et al.  Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. , 1995, Archives of ophthalmology.

[22]  Guillermo de Venecia,et al.  Cytomegalic Inclusion Retinitis in an Adult: A Clinical, Histopathologic, and Ultrastructural Study , 1971 .

[23]  J. Bennett,et al.  Gene therapy for retinitis pigmentosa. , 2000, Current opinion in molecular therapeutics.

[24]  E. Zrenner,et al.  Can subretinal microphotodiodes successfully replace degenerated photoreceptors? , 1999, Vision Research.

[25]  J. Mortimer,et al.  Visual sensations produced by optic nerve stimulation using an implanted self-sizing spiral cuff electrode , 1998, Brain Research.

[26]  D. J. Warren,et al.  A neural interface for a cortical vision prosthesis , 1999, Vision Research.

[27]  T. L. Terry Extreme Prematurity and Fibroblastic Overgrowth of Persistent Vascular Sheath Behind Each Crystalline Lens* : I. Preliminary Report , 1942 .

[28]  R. Frank Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. , 2002, American journal of ophthalmology.

[29]  B. Curtin Physiologic vs pathologic myopia: genetics vs environment. , 1979, Ophthalmology.

[30]  J. Weiss,et al.  Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. , 2001, Ophthalmology.

[31]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[32]  A. Y. Chow,et al.  Subretinal semiconductor microphotodiode array. , 1998, Ophthalmic surgery and lasers.

[33]  A. Sommer,et al.  Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. , 1991, JAMA.

[34]  Prof. J. Michel Die spontane Thrombose der Vena centralis des Opticus , 1878, Albrecht von Graefes Archiv für Ophthalmologie.

[35]  J. Herschler,et al.  Nonglaucomatous excavation of the optic disc. , 1980, Archives of ophthalmology.

[36]  J. Wyatt,et al.  REVIEW ■ : Prospects for a Visual Prosthesis , 1997 .

[37]  A. Patz THE ROLE OF OXYGEN IN RETROLENTAL FIBROPLASIA E. Mead Johnson Award Address , 1957 .

[38]  H. Quigley Recognizing structural damage to the optic nerve head and nerve fiber layer in glaucoma. , 1998, American journal of ophthalmology.

[39]  A. Milam,et al.  Morphometric analysis of the extramacular retina from postmortem eyes with retinitis pigmentosa. , 1999, Investigative ophthalmology & visual science.

[40]  R. Eckmiller Learning retina implants with epiretinal contacts. , 1997, Ophthalmic research.

[41]  W. Tasman,et al.  Multicenter trial of cryotherapy for retinopathy of prematurity. , 1988, Archives of ophthalmology.

[42]  R. E. Smith,et al.  Cytomegalovirus retinitis as the initial manifestation of the acquired immune deficiency syndrome. , 1987, American journal of ophthalmology.

[43]  W. Freeman,et al.  Cytomegalovirus retinitis and response to therapy with ganciclovir. , 1987, Ophthalmology.

[44]  N. Ashton,et al.  EXPERIMENTAL OCCLUSION OF RETINAL ARTERIOLES (USING GRADED GLASS BALLOTINI)* , 1965, The British journal of ophthalmology.

[45]  T. Hirose,et al.  Surgery for stage 5 retinopathy of prematurity. , 1987, Archives of ophthalmology.

[46]  John W. Johnson,et al.  Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. , 1995, JAMA.

[47]  J. Weiland,et al.  Pattern electrical stimulation of the human retina , 1999, Vision Research.

[48]  J. Wolter RETINAL PATHOLOGY AFTER CENTRAL RETINAL VEIN OCCLUSION* , 1961, The British journal of ophthalmology.